Keywords: priority, review, tercica, growth, agent, shares, san

Priority review for Tercica's growth agent

Article | 09 May 2005

Print This

Shares in San Francisco, California, USA-based drugmaker Tercica closed up 3.7% at $7.51 on May 2, as investors welcomed the news that the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in